Trial Profile
SOAR, Interventional Phase II Single-arm Study to Assess Efficacy and Safety of Eltrombopag Combined With Cyclosporine as First Line Therapy in Adult Patients With Severe Acquired Aplastic Anemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary) ; Eltrombopag (Primary)
- Indications Aplastic anaemia
- Focus Therapeutic Use
- Acronyms SOAR
- Sponsors Novartis Healthcare; Novartis Pharmaceuticals
- 23 May 2022 Status changed from active, no longer recruiting to completed.
- 12 Apr 2022 Planned End Date changed from 22 Jun 2022 to 8 Jun 2022.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition